OKYO Pharma Ltd（OKYO）の財務OKYOOKYO Pharma Ltd

In the context of the broader market, OKYO competes directly with industry leaders such as CNXU and QUCY. With a market capitalization of $73.47M, it holds a leading position in the sector. When comparing efficiency, OKYO's gross margin of N/A stands against CNXU's N/A and QUCY's N/A. Such benchmarking helps identify whether OKYO Pharma Ltd is trading at a premium or discount relative to its financial performance.

The company's current ratio stands at 0.40, indicating liquidity issues, and it has reported negative net income for the last two quarters, with a net loss of $2,026,474 in Q1 2026. However, total equity is projected to turn positive in Q1 2027, suggesting potential recovery.